|Bid||6.52 x 4000|
|Ask||7.32 x 900|
|Day's Range||6.32 - 7.75|
|52 Week Range||2.65 - 20.05|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2020 - Feb 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.25|
LIQ861 is an inhaled dry powder formulation of treprostinil designed using Liquidia’s PRINT® technology to enhance deep-lung delivery using a convenient, palm-sized dry powder inhaler (“DPI”) for the treatment of pulmonary arterial hypertension (PAH). Liquidia believes LIQ861 can overcome the limitations of current inhaled therapies and has the potential to maximize the therapeutic benefits of treprostinil in treating PAH by safely delivering higher doses into the lungs.
Ahead of a planned regulatory application early next year, a Triangle drugmaker has brought in more than $22 million.
Shares of Liquidia Technologies Inc. , a Durham, N.C.-based biotech, soared more than 70% Thursday before paring their gains, after Wedbush reiterated an outperform rating on the stock and said a $22.4 million fundraising will give the company the runway to keep going through the fourth quarter of 2020. The company said it sold 7.2 million shares at $3.13 a share in a private placement. Liquidia is aiming to leverage its proprietary Print technology to improve the clinical profile of approved active pharmaceutical ingredients, or APIs. The company's lead candidate called LIQ861 is a dry powder formulation of inhaled treprostinil to treat pulmonary arterial hypertension, or PAH. "In our view, LIQ861 has the potential to improve the therapeutic profile of treprostinil in treating PAH by safely delivering higher doses into the lung," Wedbush analysts led by Liana Moussatos wrote in a note to clients. The company is expecting to file a new drug application for the treatment in the first quarter of 2020. A second product candidate, LIQ865, a treatment for post-operative pain, is expected to enter phase 2 trials in 2020, said the note. Shares were last up 43% and have fallen 77% in the year to date, while the S&P 500 has gained 29%. Company plans to initiate a Phase 2 study in 2020.
The private placement is expected to close on or about December 27, 2019, subject to the satisfaction of customary closing conditions. Jefferies acted as the sole placement agent to Liquidia in connection with the private placement.
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the third quarter. We get to see hedge funds' thoughts towards the market and […]
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Completed Registrational Studies of LIQ861 to Include in New Drug Application (NDA)Targeting Submission of NDA for LIQ861 in 1Q 2020Management to Host Webcast and Conference.
NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Liquidia Technologies, Inc. (NASDAQ: LQDA ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on November 13, 2019 ...
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today.
Liquidia Technologies, Inc. (LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Katie Rielly-Gauvin, Vice President of Global Commercial Development at AbbVie, to the Company’s Board of Directors (the “Board”) as a Class II director with a term expiring at the 2020 annual meeting of stockholders and to the Company’s Research and Development Committee and Nominating & Governance Committee. “Adding Katie to our Board is another significant step in preparing Liquidia for commercial growth,” said Stephen Bloch, M.D., Chairman of the Board.
Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RESEARCH TRIANGLE PARK, N.C., Sept. 25, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company,.
“Joanna is an excellent addition to Liquidia’s Board as she is an industry veteran in drug development and commercialization across several therapeutic areas,” said Stephen Bloch, M.D., Chairman of the Board.
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company,.
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company,.
On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary PRINT® Technology Management to Host.
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.
Every investor in Liquidia Technologies, Inc. (NASDAQ:LQDA) should be aware of the most powerful shareholder groups...
Is Liquidia Technologies, Inc. (NASDAQ:LQDA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
Liquidia Technologies, Inc. (LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced that it has amended its collaboration agreement with GlaxoSmithKline (GSK) for the development and commercialization of pharmaceuticals based upon the Company’s proprietary PRINT® technology delivered through the inhalation route of administration. The amended collaboration agreement provides the Company with the right to develop and commercialize three additional PRINT®-based therapeutics delivered via inhalation. Additionally, under the amended collaboration agreement, the Company can acquire rights to pursue additional PRINT®-based programs for inhalation therapy, subject to GSK’s approval.
Results from the INSPIRE study indicates that the 75 mcg capsule strength of LIQ861 (single capsule, 1-2 breaths) correlates with the 54 mcg dose of Tyvaso® (9 breaths), the maximum recommended label dose of Tyvaso®. INSPIRE also included a one-directional, crossover sub-study to assess the comparable bioavailability and pharmacokinetics (PK) of single doses of LIQ861 and Tyvaso in 18 PAH patients. The company targets NDA submission in late 2019 that will include additional data generated from ongoing development activities.